Instrument Inactif

Communiqués Guardion Health Sciences Inc Nasdaq

Actions

US40145Q2030

Produits pharmaceutiques

Communiqués

31/10/24	Guardion Health Sciences : Announces Filing of Certificate of Dissolution Form 8 K	PU
30/10/24	Guardion Health Sciences Announces Filing of Certificate of Dissolution	AQ
03/10/24	Guardion Health Sciences : Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO Form 8 K	PU
01/10/24	Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO	AQ
21/08/24	Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock	AQ
13/08/24	Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024	AQ
31/05/24	Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution	AQ
23/05/24	Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business	AQ
21/05/24	Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company’s Special Meeting of Stockholders to be held on May 23, 2024	AQ
13/05/24	Guardion Health Sciences Announces	AQ
29/03/24	Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023	AQ
31/01/24	Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc.	AQ
13/11/23	Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023	AQ
14/08/23	Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023	AQ
05/06/23	GUARDION HEALTH SCIENCES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
30/05/23	Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive Officer	AQ
15/05/23	Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023	AQ
17/04/23	Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022	AQ
17/04/23	GUARDION HEALTH SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
07/03/23	GUARDION HEALTH SCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/03/23	Guardion Health Sciences Hires Alantra, LLC as its Financial Advisor to Explore Strategic Alternatives to Maximize Stockholder Value	AQ
24/01/23	GUARDION HEALTH SCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
24/01/23	Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements	AQ
06/01/23	GUARDION HEALTH SCIENCES, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/01/23	Guardion Health Sciences, Inc. Announces 1-for-50 Reverse Stock Split Effective on Pre-Market Opening on January 9, 2023	AQ